COVERAGE
Mich. Justices Reject Credit Suisse’s NOL Carryforward Bid
February 28, 2025
Read time: 2 min

COVERAGE
February 28, 2025
Read time: 2 min

COVERAGE
February 28, 2025
Read time: 2 min

COVERAGE
February 28, 2025
Read time: 2 min

COVERAGE
February 28, 2025
Read time: 2 min

COVERAGE
Feburary 28, 2025
Read time: 3 min
The SEC’s new guidance on investor activism related to Schedule 13D and 13G filings has caused confusion among asset managers, leading to the temporary pause of meetings by some of the industry’s largest firms. The guidance requires investment firms pressuring companies on ESG issues to file the more detailed Schedule 13D.
While the difference between filing a Schedule 13G and 13D is significant, Schulte Roth and Zabel partner Ele Klein identifies how the perception difference could have an impact on dynamics between companies and shareholders. “Amendment requirements are much more onerous, and the status of being a 13D filer is perceived drastically differently than being a 13G filer by companies, meaning that it may chill conversations and may chill the perception of someone being a friendly shareholder or a cooperative shareholder or a non-threatening shareholder, now it is switched into totally different modes,” Ele stated.
The potential impact of this guidance on ESG investing is uncertain and has caused marked confusion. As Ele explains, “So, what people will do, we’ll see. I actually don’t think it’s going to cause drastic change. It’s going to cause a lot of people to be thinking about things. It may, we’ll see, chill certain conversations that I think companies would appreciate having so I do think, it can have a negative effect on the market from both investor side and company side.”
Read the article.

COVERAGE
February 26, 2025
Read time: 2 min

COVERAGE / DEAL ANNOUNCEMENT / PRESS RELEASE
February 26, 2025
Read time: 3 min
Frankfurt, February 26, 2025 – McDermott Will & Emery has advised German digital health company Kranus Health on the conclusion of a cooperation agreement with Gedeon Richter Pharma GmbH.
As strategic partners, both companies aim to advance digital care in gynecology and specifically support the market entry and marketing of Kranus Mictera, an innovative digital therapy for the treatment of female incontinence.
Kranus Health GmbH based in Berlin and Munich, Germany, and with a branch in Paris, France, specializes in digital therapy programs, particularly in the field of urology.
German-based Gedeon Richter Pharma GmbH is a subsidiary of the specialty pharmaceutical company Gedeon Richter Plc. headquartered in Hungary. With 41 branches and over 12,800 employees worldwide, Gedeon Richter is one of the most successful pharmaceutical companies in the fields of women’s health, neuropsychiatry, biotechnology and general medicine.
McDermott advised Kranus Health with a team led by partner Monika Richter.

COVERAGE
February 25, 2025
Read time: 2 min

COVERAGE
February 25, 2025
Read time: 2 min

COVERAGE
February 25, 2025
Read time: 2 min